tbuckley/cabot-search huggingface dataset:
FRI0419 Big Data Sjogren Project (Eular-SS Task Force International Network): Systemic Involvement at Diagnosis Evaluated by the Essdai in 3314 Patients with Primary Sjögren Syndrome
Authors: P. Brito Zeron, B.A. Kostov, R. Seror, C. Baldini, L. Quartuccio, M. Kvarnstrom, A. Kruize, G. Hernández Molina, S. Praprotnik, E. Bartoloni, R. Solans, E. Theander, V. Valim, R. Priori, M. Zeher, D. Isenberg, A. Rasmussen, R. Giacomelli, S. Carsons, D. Hammenfors, C. Vollenweider, F. Atzeni, T. Mandl, S. De Vita, M. Wahren-Herlenius, J. Sanchez-Guerrero, R. Gerli, K. Sivils, S. Mowa, J.G. Brun, X. Mariette, M. Ramos-Casals
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> To characterize and quantify systemic involvement at diagnosisinalarge international cohort of patients diagnosed with primary Sjogren syndrome (SS). <h3>Methods</h3> The Big Data Sjögren Project is an international, multicenter registry formed in 2014 with the aim of taking a "high-definition" picture of the main features of primary SS at diagnosis by merging international SS databases. By January 2015, the database included 5027 consecutive patients fulfilling the 2002 classification criteria for primary SS from 13 countries (9 European, 4 American). Systemic involvement was defined according to the ESSDAI and retrospectively calculated. <h3>Results</h3> Baseline ESSDAI data was collected in3314 patients (94% female, mean age at diagnosis 54.25 years). The main features of systemic involvement at diagnosis included biological activity in 43%of patients, articular involvement in 35%, hematological activity in 25%and glandular involvementin 19%. The mean ESSDAI score at diagnosis of the entire cohort was 5.63 (range, 0-62). Low DAS was reported in 1267 (38%) patients, moderate DASin 943 (28%) and high DAS in 378 (11%) patients; in the remaining 726 patients (22%), the ESSDAI score at diagnosis was 0. The mean baseline ESSDAI was higher in males (7.33 vs 5.52, p&lt;0.001), patients diagnosed ≤35 years (6.71 vs 5.63, p=0.001), those with positive ocular tests (5.75 vs 4.98, p=0.023) and those with positive immunological markers including ANA (6.71 vs 4.63, p&lt;0.001), RF (7.46 vs 5.49, p&lt;0.001), anti-Ro/SSA (6.77 vs 5.48, p&lt;0.001) and anti-La/SSB (6.91 vs 6.0, p&lt;0.001). According to the number of criteria fulfilled at diagnosis, a higher mean baseline ESSDAI was found in patients fulfilling the six criteria (7.67 vs 5.65 in those fulfilling 5 criteria and 5.23 in those fulfilling 3-4 criteria, p&lt;0.001). <h3>Conclusions</h3> Epidemiological features (male sex, younger age at diagnosis) and positive autoantibodies at diagnosis were closely-related to greater systemic activity. Using the ESSDAI in real-life situations may help identify epidemiological and immunological subsets with high systemic activity at diagnosis and, therefore, at high risk of suffering a complicated clinical course. <h3>Disclosure of Interest</h3> None declared
Serum Levels of the Carboxy-Tervninal Propeptide of Type I Procollagen and the Pyridinoline Cross-Linked Carboxy-Terminal Telopeptide of Type I Collagen as Markers of Bone Metastases in Patients with Prostate Carcinoma
Authors: Yoshikatsu Hosoya, Kyoko Arai, Mikihiko Honda, Shuhei Sumi, Ken-ichiro Yoshida
Journal: European Urology (1997)
AB0589 Involvement of Peripheral Nervous System in Primary SjÖgren Syndrome. a Gessar Analisys
Authors: M.M. Mayer, S.D. Velez, F. Zazzetti, L. Galván, G. Bennasar, L.R. Carlevaris, A. Secco, C. Asnal, P. Pucci, C. Amitrano, A. Nitsche, M.C. Khoury, F. Caeiro, N. Benzaquén, J.P. Pirola, M. Colazo, O.L. Rillo, S. Papasidero, J. Demarchi, L. Raitti, M.N. Tamborenea, M.L. Santiago, P. Alba, B. Busamia, G. Salvatierra, A. Catalán Pellet, J.C. Barreira
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Peripheral neuropathy (PN) is usually is a late onset event in primary Sjögren Syndrome (pSS) associated with purpura, cryoglobulinemia, hypocomplementemia and increased risk of lymphoma. <h3>Objectives</h3> To describe the frequency of PN in patients with pSS and identify related factors. <h3>Methods</h3> Adult patients in the GESSAR database who met 2002 criteria for pSS. Demographic, clinical, laboratory and electromyogram (EMG) findings were recorded. PN was defined with clinic manifestations and EMG. Other causes of PN were excluded. To compare groups, all patients with PN were included (cases) and a random sample of patients without PN (controls) with a 1:4 ratio was used. Mann-Whitney was used for numeric variables and χ<sup>2</sup>or Fisher9s for categorical. An α of 0.05 was considered significant. <h3>Results</h3> Of 368 patients, 95% were female. Mean age at analysis was 55 y/o (21-87) and 50 y/o (20-89) at diagnosis. The frequency of PN was 11.68% (43/368). Sensory PN was found in 63% (28/43), predominantly small fibers involvement in 41.8% (18/43), axonal PN in 20.9% (9/43) and ataxic in 2.3% (1/43). Somatosensory manifestations were found in 37% (16/43) with axonal involvement in 30.2% (13/43) and mononeuritis multiplex in 6.9% (3/43), none had autonomic PN. When comparing groups (43 vs 172 controls) patients with PN had a higher frequency of vasculitis (11.7% vs 1.7%; p=0.002), purpura (23.8% vs 4.7%, p=0.0001), renal tubular acidosis (7.6% vs 1.2%, p=0.020), leucopenia (30.7% vs. 12.1%, p=0.005), low C3 (48.5% vs. 10.3%, p=0.0001) and C4 (66.6% vs. 18.2%, p=0.0001), (+) Anti-Ro/SSA (85.3% vs. 66.6%, p=0.019), (+) RF (72.5% vs. 52.1%, p=0.022), cryoglobulinemia (42.1% vs. 10.9%, p=0.0001) and higher frequency of hypergammaglobulinemia (60.5% vs 44.6%, p=0.09), Raynaud9s (27.5% vs 11.6%, p=0.051) and glomerulonephritis (4.6% vs 0.5%, p=0.018), although without statistical significance. <h3>Conclusions</h3> The frequency of PN was 12%, similar to other cohorts. Small fibers and axonal somatosensory PN were the most common. PN was significantly associated with vasculitis, purpura, renal tubular acidosis, cryoglobulinemia, leucopenia, hypocomplementemia and anti-Ro and RF positivity. <h3>Disclosure of Interest</h3> None declared
WHO open to “lobbying” by business
Authors: Anne Gulland
Journal: BMJ (2016)

The World Health Organization has been warned that it was now open to undue influence from commercial interests after member states agreed a framework for its relations with industry and other bodies.

Delegates at last week’s World Health Assembly in Geneva agreed the Framework for Engagement with Non-State Actors , a document that set out rules for the organisation’s relationship with bodies from industry, academia, and non-governmental organisations (NGOs) and philanthropic organisations.

Member states spent the last two years negotiating the framework, which WHO described as a “major step in WHO’s governance reform.” It said that the framework gave the organisation “comprehensive policies and procedures” on engagement with such bodies.

“The …
Fabrication of 3D Biomimetic Microfluidic Networks in Hydrogels
Authors: Keely A. Heintz, Michael E. Bregenzer, Jennifer L. Mantle, Kelvin H. Lee, Jennifer L. West, John H. Slater
Journal: Advanced Healthcare Materials (2016)

A laser-based hydrogel degradation technique is developed that allows for local control over hydrogel porosity, fabrication of 3D vascular-derived, biomimetic, hydrogel-embedded microfluidic networks, and generation of two intertwining, yet independent, microfluidic networks in a single construct.
OC-087 Randomised trial of enteral feeding in patients discharged from hospital following surgical resection of an upper gastrointestinal malignancy
Authors: F Froghi, G Sanders, T Wheatley, R Berrisford, P Peyser, J Rahamim, S Lewis
Journal: Gut (2015)

<h3>Introduction</h3> Patients undergoing upper gastrointestinal surgery often eat poorly post operatively, despite dietetic input. The benefit of nutritional supplementation following hospital discharge is unknown. We examined the benefit of 6 weeks nutritional supplementation via the patients feeding jejunostomy on fatigue, quality of life and independent living. <h3>Method</h3> Patients undergoing oesophagectomy or total gastrectomy for cancer had a feeding jejunostomy placed routinely at surgery. Jejunal feeding was started postoperatively and if tolerated at discharge consenting patients were randomly allocated (stratified by gastric/oesophageal) to nutritional supplementation (600 Kcal/day) via their feeding jejunostomies or no jejunal supplement. All patients received oral supplements and dietetic input. Patients were assessed at discharge and 3, 6, 12 and 24 weeks following discharge for fatigue (MFI-20), quality of life (EORTC QLQ-OES18), health economic analysis (independent living: EQ5D) as well as completing 2 day dietary diaries. Results were analysed non-parametrically (Mann-Whitney) and data presented as medians with interquartile ranges. <h3>Results</h3> 44 patients (M:F 29:15) were randomised, 23 received jejunal supplements. There was no difference between the groups in age, sex, neo-adjuvant chemotherapy, ASA grade, type of operation, operative time, blood loss, length of hospital stay, and inpatient complications. Percentage of calculated energy requirement actually received was greater in the supplemented group at weeks 3 and 6 (p &lt; 0.0001). Jejunal supplementation did not suppress oral energy intake. There was no difference between the two groups for oral energy intake at any time period. No complications were seen from jejunal feeding in the community. After hospital discharge, scores for MFI-20, EQ5D and EORTC QLQ-OES18 were not different between groups at any time point. From hospital discharge fatigue improved and plateaued at 6 weeks (p &lt; 0.05 for both groups), independence at 12 weeks (p &lt; 0.05 for both groups) but no improvement was seen in quality of life until 24 week in the active group alone (p &lt; 0.02) and not at all in the control group. <h3>Conclusion</h3> Dietary intake following hospital discharge after oesophageal or gastric surgery is poor. Addition of jejunal feeding over and above dietary advice and sip feeds is effective in providing patients with an adequate energy intake. Increased energy intake however, produced no obvious improvement in measures of fatigue, quality of life or health economics. Interestingly improvement in fatigue and independence plateaued by 12 weeks whilst there was little evidence of improvement in quality of life at 24 week. <h3>Disclosure of interest</h3> None Declared.
Enzymatic Hydrolysis of Acetyldehydroalanine
Authors: Jose M. Gonçalves, Vincent E. Price, Jesse P. Greenstein
Journal: JNCI Journal of the National Cancer Institute (1947)

Journal Article Enzymatic Hydrolysis of Acetyldehydroalanine Get access Jose M. Gonçalves, Jose M. Gonçalves Rockefeller Foundation Fellow Search for other works by this author on: Oxford Academic PubMed Google Scholar Vincent E. Price, Vincent E. Price assistant surgeon Search for other works by this author on: Oxford Academic PubMed Google Scholar Jesse P. Greenstein Jesse P. Greenstein chief biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 6, June 1947, Pages 443–446, https://doi.org/10.1093/jnci/7.6.443 Published: 01 June 1947 Article history Received: 01 April 1947 Published: 01 June 1947
Endocrine Methods of Treatment of Cancer of the Breast&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;3&lt;/xref&gt;
Authors: Charles Huggins
Journal: JNCI Journal of the National Cancer Institute (1954)

Journal Article Endocrine Methods of Treatment of Cancer of the Breast Get access Charles Huggins Charles Huggins Ben May Laboratory for Cancer Research, University of Chicago, Chicago, Ill. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 1, August 1954, Pages 1–25, https://doi.org/10.1093/jnci/15.1.1 Published: 01 August 1954 Article history Received: 22 March 1954 Published: 01 August 1954
2-Chlorodeoxyadenosine: drug development priorities.
Authors: L D Piro
Journal: Journal of Clinical Oncology (1992)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1992.10.10.1507 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 1357106 2-Chlorodeoxyadenosine: drug development priorities. L D PiroxL D PiroSearch for articles by this author https://doi.org/10.1200/JCO.1992.10.10.1507 First Page PDF © 1992 by American Society of Clinical Oncology
mTORC1 promotes aging-related venous thrombosis in mice via elevation of platelet volume and activation
Authors: Jun Yang, Xuan Zhou, Xiaorong Fan, Min Xiao, Dinghua Yang, Bo Liang, Meng Dai, Lanlan Shan, Jingbo Lu, Zhiqi Lin, Rong Liu, Jun Liu, Liping Wang, Mei Zhong, Yu Jiang, Xiaochun Bai
Journal: Blood (2016)
A possible foodborne outbreak of hepatitis A in the Netherlands, January-February 2010
Authors: M Petrignani, L Verhoef, R van Hunen, C Swaan, J van Steenbergen, I Boxman, H J Ober, H Vennema, M Koopmans
Journal: Eurosurveillance (2010)

As of 1 March 2010, a total of 11 primary cases with onset of symptoms between 31 December 2009 and 10 February 2010, have been identified with identical hepatitis A genotype IB strains in the Netherlands. A relation with Australian and French foodborne outbreaks occurring in 2009 and 2010 is suspected. Ten of the 11 primary cases indicated that they had consumed one or more products containing semi-dried tomatoes during their incubation period.
Earn-as-you-go pressures in academic psychiatry
Authors: F G Guggenheim, C Nadelson
Journal: American Journal of Psychiatry (1984)

The future of academic psychiatry may be seriously jeopardized by recent funding cutbacks at federal and state levels. Hospitals and departments of psychiatry are having to function as businesses, and full-time faculty are increasingly concerned with profits, with less time for teaching. Shrinking departmental resources make it necessary for faculty to assume the new responsibility--in addition to their administrative, educational, and teaching roles--of generating large portions of their own salaries from private patient care revenues. Residents' opportunities to work with psychotherapy patients are being compromised by financial considerations. Other actual or potential consequences of the fiscal dilemma include decreased teaching of medical students and lessened scholarly productivity.
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases
Authors: Jing Ni, Shakti H Ramkissoon, Shaozhen Xie, Shom Goel, Daniel G Stover, Hanbing Guo, Victor Luu, Eugenio Marco, Lori A Ramkissoon, Yun Jee Kang, Marika Hayashi, Quang-De Nguyen, Azra H Ligon, Rose Du, Elizabeth B Claus, Brian M Alexander, Guo-Cheng Yuan, Zhigang C Wang, J Dirk Iglehart, Ian E Krop, Thomas M Roberts, Eric P Winer, Nancy U Lin, Keith L Ligon, Jean J Zhao
Journal: Nature Medicine (2016)
Sleep-wake disturbance in patients with brain tumors
Authors: Terri S. Armstrong, Marcia Y. Shade, Ghislain Breton, Mark R. Gilbert, Anita Mahajan, Michael E. Scheurer, Elizabeth Vera, Ann M. Berger
Journal: Neuro-Oncology (2016)

Sleep-wake disturbances are defined as perceived or actual alterations in sleep that result in impaired daytime functioning. Unlike other cancers, there is limited information about sleep-wake disturbances in adults with primary brain tumors throughout the illness trajectory. Sleep-wake disturbance is among the most severe and common symptoms reported by primary brain-tumor patients, particularly those undergoing radiation therapy. As with other cancers and neurologic illness, sleep-wake disturbance may also be clustered or related to other symptoms such as fatigue, depression, and cognitive impairment. There is increasing evidence for a genetic basis of normal sleep and sleep regulation in healthy adults. Specific mutations and single nucleotide variants have been reported to be associated with both fatigue and sleep-wake disorders, and both inflammation and alterations in circadian rhythms have been postulated to have a potential role. Guidelines for assessment and interventions have been developed, with cognitive behavioral therapy, exercise, and sleep hygiene demonstrating benefit in patients with other solid tumors. Further research is needed to identify risk and appropriate treatment in the brain-tumor patient population.
Toxicity of Triparanol for the Turkey Poult
Authors: R A BALL, J H SAUTTER, R E BURGER
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Glycolysis determines dichotomous regulation of T cell subsets in hypoxia
Authors: Yang Xu, Arindam Chaudhury, Ming Zhang, Barbara Savoldo, Leonid S. Metelitsa, John Rodgers, Jason T. Yustein, Joel R. Neilson, Gianpietro Dotti
Journal: Journal of Clinical Investigation (2016)

Hypoxia occurs in many pathological conditions, including chronic inflammation and tumors, and is considered to be an inhibitor of T cell function. However, robust T cell responses occur at many hypoxic inflammatory sites, suggesting that functions of some subsets are stimulated under low oxygen conditions. Here, we investigated how hypoxic conditions influence human T cell functions and found that, in contrast to naive and central memory T cells (TN and TCM), hypoxia enhances the proliferation, viability, and cytotoxic action of effector memory T cells (TEM). Enhanced TEM expansion in hypoxia corresponded to high hypoxia-inducible factor 1α (HIF1α) expression and glycolytic activity compared with that observed in TN and TCM. We determined that the glycolytic enzyme GAPDH negatively regulates HIF1A expression by binding to adenylate-uridylate-rich elements in the 3'-UTR region of HIF1A mRNA in glycolytically inactive TN and TCM. Conversely, active glycolysis with decreased GAPDH availability in TEM resulted in elevated HIF1α expression. Furthermore, GAPDH overexpression reduced HIF1α expression and impaired proliferation and survival of T cells in hypoxia, indicating that high glycolytic metabolism drives increases in HIF1α to enhance TEM function during hypoxia. This work demonstrates that glycolytic metabolism regulates the translation of HIF1A to determine T cell responses to hypoxia and implicates GAPDH as a potential mechanism for controlling T cell function in peripheral tissue.
Quality and Safety in Health Care, Part II
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2015)

The 1990 Institute of Medicine report Medicare: A Strategy for Quality Assurance offered a definition of quality in health care and recommendations on how to achieve it. The forces for change would include different activities by the federal government, informed consumers, professionalism, and private initiatives. Eight years later, the National Roundtable report Statement on Quality of Care indicated that there were major problems of underuse, overuse, and misuse of health care services. In the same year, the President's Advisory Commission report Quality First: Better Health Care for All Americans discussed major problems with health care and proposed many initiatives to correct them, and also recommended a Bill of Rights and Responsibilities for the patients.
Occurrence and lung cancer probability of new solid nodules at incidence screening with low-dose CT: analysis of data from the randomised, controlled NELSON trial
Authors: Joan E Walter, Marjolein A Heuvelmans, Pim A de Jong, Rozemarijn Vliegenthart, Peter M A van Ooijen, Robin B Peters, Kevin ten Haaf, Uraujh Yousaf-Khan, Carlijn M van der Aalst, Geertruida H de Bock, Willem Mali, Harry J M Groen, Harry J de Koning, Matthijs Oudkerk
Journal: The Lancet Oncology (2016)
THU0032 Selective, Autoantibody-Immune Complex Mediated Proportional and Functional Changes of Specific NK-Cell Subsets in Early Seropositive but not Seronegative Rheumatoid Arthritis
Authors: P. Chalan, E. Brouwer, J. Bijzet, B.-J. Kroesen, M. Boots
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Despite substantial data demonstrating NK-cell impairment in rheumatoid arthritis (RA), the exact role of NK-cells in RA immunopathogenesis remains unclear. <h3>Objectives</h3> We studied the involvement of CD56dim and CD56bright NK-cells in the early stages of RA development to elucidate their role in the pathogenesis of RA. <h3>Methods</h3> The study included newly diagnosed RA patients and seropositive arthralgia patients (SAP), representing subjects at risk of progression to RA. Whole blood samples obtained from disease modifying anti rheumatic drug (DMARD)-free RA patients at the time of diagnosis (autoantibody -positive [SP RA, n=45] and -negative [SN RA, n=12]); SAP (n=30) and healthy controls (HC, n=41), were studied to assess absolute numbers and proportions of T-cells, B-cells and NK-cells. Peripheral blood mononuclear cells (PBMC) were used for both phenotypical and functional analyses of NK-cells in the studied groups. <h3>Results</h3> Patients (SP RA and SAP) positive for anti-cyclic citrullinated protein antibodies (ACPA) and/or rheumatoid factor (RF) showed decreased total NK-cell numbers. Also, NK-cells from SP RA showed a decreased potency for IFN-γ production. NK-cell subset analysis demonstrated a specific decrease of CD56dim, but not CD56bright NK-cells in SP RA and SAP. Differential NK-cell alterations in seropositive and seronegative patients prompted the investigation of the role of CD16 (FcγRIIIa) triggering in apoptosis induction and cytokine expression by CD56dim and CD56bright NK-cell subsets. CD16 triggering in vitro induced apoptosis of CD56dim, but not CD56bright NK-cells, and was augmented by the addition of IL-2. Also, CD16 triggering in the presence of IL-2 stimulated IFN-γ expression by CD56dim NK-cells. <h3>Conclusions</h3> The decline of CD56dim NK-cells is an early feature in the development of seropositive, but not seronegative RA. The decline of CD56dim NK-cells in SAP and SP RA and observed in vitro apoptosis of CD56dim NK-cells upon CD16 triggering, suggests a functional role of IgG-containing autoantibody (ACPA and/or RF)-immune complexes in CD16-mediated apoptosis. Moreover, CD16 triggering leads to an increased cytokine response by CD56dim NK-cells, which may contribute to the proinflammatory state in both SP RA and SAP. <h3>Disclosure of Interest</h3> None declared